A novel HER2-targeted antibody-drug conjugate offers the possibility of clinical dosing at trastuzumab-equivalent exposure levels
R. M. Barfield, Y. C. Kim, S. Chuprakov, F. Zhang, M. Bauzon, A. O. Ogunkoya, D. Yeo, C. Hickle, M. D. Pegram, D. Rabuka, P. M. Drake
This paper develops a novel HER2-targeted ADC, CAT-01-106, showing improved efficacy and tolerability compared to T-DM1 at equivalent payload dosing.
bioRxiv · Mar 13, 2020Pharmacology & Toxicology